The pathogenesis of acute promyelocytic leukemia involves the transcriptional repression of master genes of myeloid differentiation by the promyelocytic leukemia-retinoic acid receptor ␣ (PML͞ RARA) oncogene. PML-enforced RARA homodimerization allows the tighter binding of corepressors, silencing RARA target genes. In addition, homodimerization dramatically extends the spectrum of DNA-binding sites of the fusion protein compared with those of normal RARA. Yet, any contribution of these two properties of PML͞RARA to differentiation arrest and immortalization of primary mouse hematopoietic progenitors was unknown. We demonstrate that dimerization-induced silencing mediator of retinoid and thyroid receptors (SMRT)-enhanced binding and relaxed DNAbinding site specificity are both required for efficient immortalization. Thus, enforced RARA dimerization is critical not only for triggering transcriptional repression but also for extending the repertoire of target genes. Our studies exemplify how dimerization-induced gain of functions converts an unessential transcription factor into a dominant oncogenic protein.
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chromatin ͉ leukemia ͉ retinoic acid ͉ transcription T he t(15;17) chromosomal translocation, specific for acute promyelocytic leukemia (APL), fuses the promyelocytic leukemia (PML) gene to the retinoic acid receptor ␣ (RARA) gene. APL leukemogenesis primarily involves transcriptional silencing of critical differentiation genes by the PML-RARA fusion protein (1) , which results in both a differentiation block and expansion of myeloid progenitors. Yet, although several structure͞function studies have been performed in various immortalized cell lines, with transcriptional repression or differentiation block as an outcome, the molecular determinants of differentiation arrest and͞or immortalization in primary hematopoietic cells are largely unexplored. At the molecular level, two distinct domains of the fusion protein cooperate to enforce transcriptional repression: (i) the RARA hormone-binding domains, dimerized by the PML coiled coil, recruit silencing mediator of retinoid and thyroid receptors (SMRT) with a much greater affinity than RARA͞retinoid X receptor (RXR) heterodimers (2-6); (ii) a specific sumoylation site in PML is required for full repression (7) . In contrast to RAR͞RXR heterodimers, which bind DNA sites that consist of two AG-GTCA core motifs in a direct-repeat orientation, with spacing of 1, 2, or 5 (8, 9) , PML͞RARA forms homodimers or multimers with RXR that tightly bind two core motifs, in any orientation, even with very wide spacing (10) (11) (12) . Accordingly, PML͞RARA was first shown to silence RA target genes (13) , then type II nuclear receptor targets (10, 11) , and finally de novo target genes such as type II transglutaminase or CCAAT͞enhancer-binding protein ␤, many of which contain widely spaced binding sites (12, (14) (15) (16) . Whether these de novo targets of the fusion protein are simple bystanders or play a critical role in transformation is unknown. The upstream partners of RARA in the X-RARA fusions [PML and promyelocytic leukemia zinc finger (PLZF)] not only provide a dimerization interface and an additional repression domain to the fusion (2-4, 7, 17) , but they could also contribute to transformation through deregulation of the pathways normally controlled by PML or PLZF (1). By transducing a set of RARA mutants in primary hematopoietic progenitor cells, we establish that dimerization-induced enhanced SMRT binding and repression of PML͞RARA-specific targets are both critical to differentiation arrest and immortalization, demonstrating how dimerization converts RARA into an oncogenic protein.
Results

RARA Homodimerization Is Required for Transformation of Primary
Mouse Hematopoietic Progenitors. Primary hematopoietic progenitor cells undergo a sharp differentiation arrest and become immortal after transduction of PML͞RARA (7, 18, 19) . Self-dimerizing RARA mutants, such as p50-RARA, which recruit SMRT and efficiently silence nuclear receptor target genes, were proposed to play a critical role in APL pathogenesis (5, 6 ). Yet, this fusion failed to immortalize mouse progenitors ( Fig. 1) , consistent with the requirement of an additional small ubiquitin-like modifier of protein (SUMO)dependent repression for transformation of primary cells (7) . In the context of PML͞RARA, the transcriptional corepressor Daxx can replace this SUMO-dependent repression domain (7) . Expression of a Daxx-RARA fusion protein also failed to immortalize or induce a significant differentiation block in these progenitor cells ( Fig. 1) .
To address the contribution of RARA dimers to transformation, we inserted the tetramerization domain of p53 (not including the sumoylation site) into Daxx-RARA. When transduced into progenitor cells, Daxx-tet-RARA was as efficient as PML͞RARA in blocking their differentiation and immortalizing them ( Fig. 1) , thus demonstrating the crucial role of dimerization in transformation of primary cells ex vivo. To assess directly the role of enhanced SMRT recruitment in immortalization, mutations in RARA previously shown to abrogate SMRT binding (4) were introduced into Daxx-tet-RARA. Although these mutations impaired immortalization, Abbreviations: APL, acute promyelocytic leukemia; DR, direct repeat; Luc, luciferase; MEF, mouse embryo fibroblast; NCoR, nuclear receptor corepressor; PLZF, promyelocytic leukemia zinc finger; PML, promyelocytic leukemia protein; RA, retinoic acid; RARA, retinoic acid receptor ␣; RXR, retinoid X receptor; SMRT, silencing mediator of retinoid and thyroid receptors; SUMO, small ubiquitin-like modifier of protein; tet, tetramerization domain; Tk, thymidine kinase.
demonstrating the importance of enhanced SMRT binding to this process, Daxx-tet-RARA*NCoR expression nevertheless triggered a very significant differentiation block when expressed in myeloid progenitors (Fig. 1C ). Comparable levels of these different RARA fusions were expressed after retroviral transduction ( Fig. 2A ). As expected, only PML͞RARA was able to delocalize PML nuclear bodies (data not shown), but all of the RARA fusions had a finely trabecular and microspeckled nuclear localization (data not shown). Altogether, these findings demonstrate that Daxx and SMRT repression domains, as well as dimerization, are indispensable for complete differentiation block and immortalization of primary hematopoietic precursor cells ex vivo.
Binding Specificity of RARA Mutants. To demonstrate directly that Daxx-tet-RARA shares with PML͞RARA altered binding site specificity, we monitored the binding of these proteins onto direct-response elements DR5, DR8, and DR12. A specific retarded protein-DNA complex was observed when extracts of Daxx-tet-RARA-transfected CHO cells, but not untransfected ones, were added to either of the probes, demonstrating that Daxx-tet-RARA, like PML͞RARA (12), can bind an extended repertoire of response elements ( Fig. 2 and data not shown). Identical results were obtained in the presence of RXR (data not shown).
Enforced RARA dimerization results in an increased affinity for SMRT (5, 6) . When bacterially expressed SMRT was added to binding reactions, PML͞RARA or Daxx-tet-RARA bound SMRT very avidly, whereas, as expected, RARA-RXR, Daxx-RARA, or Daxx-tet-RARA*NCoR did not ( Fig. 2B and data not shown). Thus, Daxx-tet-RARA is similar to PML͞RARA with respect to SMRT and DNA binding as well as transformation ex vivo.
Control of Gene Expression by RARA Mutants.
To establish that the different RARA fusions described above regulate distinct sets of genes, as expected from the different binding site specificity, we first expressed them in immortalized mouse fibroblasts, where all three RARs were excised by Cre recombinase (20) . Thus, in these cells, any retinoic acid (RA)-induced change in gene transcription is exclusively dependent on a transduced RARAderived receptor. We first transiently transfected DR5-or DR12containing reporter plasmids (12) and examined the effect of RA on luciferase activity. Remarkably, whereas RARA or Daxx-RARA activated the DR5 reporter almost exclusively, PML͞ RARA, Daxx-tet-RARA, or Daxx-tet-RARA*NCoR activated either of the DR5 or DR12 reporters after the addition of hormone (Fig. 3A) .
To demonstrate further the relaxed specificity of target-gene activation by RARA homodimers, we analyzed RA-dependent transcriptional activation of three target genes by quantitative PCR. We focused on three genes: two well characterized RARA targets (RARB and CYP26A1) and a primary PML͞RARA target, transglutaminase type II (14) . As expected, for the RARB or CYP26A1 genes, RA activated all of the RARA-derived receptors (Fig. 3A) , the strongest activation being observed for RARA and Daxx-tet-RARA*NCoR. Enhanced binding of corepressors onto self-dimerizing RARA fusions blunted the response to RA, as expected. Remarkably, proteins containing a dimerization domain (notably, PML͞RARA, Daxx-tet- RARA, and Daxx-tet-RARA*NCoR) all activated the transglutaminase type II gene, whereas Daxx-RARA and wild-type RARA failed to do so. This observation strongly suggests that this gene contains an as yet unidentified response element specific for RARA dimers, and it points to the importance of RARA dimerization in the extension of the target-gene repertoire.
Altered Binding Site Specificity by Dimerization Is Key to the APL
Phenotype. The findings presented above demonstrate that Daxxtet-RARA recapitulates all of the transformation-and transcription-associated phenotypes of PML͞RARA, presumably through dimerization-induced SMRT recruitment and͞or relaxed DNA-binding site specificity. Defective immortalization by Daxx-tet-RARA*NCoR demonstrates that corepressor binding is essential for transformation of primary cells by RARA homodimers. To investigate the importance of dimerizationinduced extension in the target-gene repertoire, we generated Daxx-SMRT-RARA, a construct in which the repression domain of SMRT (21) was inserted into Daxx-RARA, thus dissociating from RARA homodimerization the enhanced binding of SMRT onto RARA. Importantly, this construct (which was expressed at levels similar to the other RARA fusions) did not induce a differentiation block and did not immortalize primary hematopoietic progenitors (Fig. 4A) .
To demonstrate unambiguously that both of the two repression domains are functional in this large fusion protein, we compared the ability of Daxx-RARA and Daxx-SMRT-RARA to regulate transcription in the different settings explored above. In contrast to Daxx-RARA, Daxx-SMRT-RARA was incapable of activating the endogenous RARB or CYP26A1 gene in transduced RAR-null cells (Fig. 4B ). In transient transfections by a DR5-derived reporter (8) of RAR ϩ/ϩ MEFs stably transduced by Daxx-SMRT-RARA, this fusion blunted the RA response mediated by endogenous RARs, whereas Daxx-RARA enhanced luciferase induction by RA (Fig. 4C) . Similar results were obtained in HeLa or COS cells transiently cotransfected with the reporter plasmid and an expression vector for Daxx-SMRT-RARA (data not shown). Finally, in RAR ϩ/ϩ MEFs, activation of the endogenous RARB gene by RA was sharply diminished by stably expressed Daxx-SMRT-RARA, but it was activated by Daxx-RARA (Fig. 4C) . That Daxx-SMRT-RARA does not significantly affect the differentiation of hematopoietic progenitors cells, despite the efficient tethering of the two critical repression domains onto RAR͞RXR targets, demonstrates that altered DNA sequence recognition elicited by enforced RARA homodimerization is also critical to the APL phenotype. 
Discussion
RARA dimerization triggers both the efficient recruitment of SMRT-NCoR corepressors (5, 6) and a dramatically relaxed DNA-binding specificity (12) . In the context of APL fusion proteins, PLZF and PML also provide an additional repression domain (2-4, 7) . These three events cooperate to repress any gene that contains two AGGTCA half-sites in any orientation or spacing (12, 15) . Although previous studies in cell lines had demonstrated the importance of RARA dimerization and SMRT binding in the differentiation block (4-6), the contribution of these three gains of function of APL fusions in primary cells was not established.
This work, consistent with three very recently published reports (22) (23) (24) , demonstrates the critical role of RARA dimerization in the immortalization of primary myeloid progenitors. Note that all APL-associated RARA fusion proteins contain a potent dimerization domain (25) . Although RARA dimerization through the rapamycin-sensitive FKBP domain was suggested to suffice for ex vivo transformation (22) , our own results with p50-RARA ( Fig. 1) , as previously with PML͞RARA-K160R (7) , suggest that enforced RARA dimerization is insufficient per se. Although this discordance may relate to the experimental conditions, such as the mouse strains used or the cytokine content of the assay, we note that, in our hands, demonstration of immortalization requires more than three passages in methyl cellulose (7) and that the FKBP artificial dimerization module contains a consensus sumoylation site (26) that may complicate the interpretation of experiments performed with FKBP-enforced RARA dimers (22) .
Relaxed DNA-binding specificity by RARA homodimers also appears to be critical to the immortalization of primary cells, strongly suggesting that non-RARA targets of the fusions play a critical role in transformation and identifying a critical gain of function of PML͞RARA. This conclusion is in line with the observation that a dimerization-deficient PLZF͞RARA mutant failed to transform myeloid progenitors, although it retained a greatly enhanced binding to the SMRT corepressor at the biochemical level (22) . Note that the v-ErbA oncogene (27) and PLZF͞RARA (D. Kamashev and H.d.T., unpublished observations) also have an extended repertoire of DNA-binding sites compared with their parental nuclear receptors, suggesting that dimerization-induced change in DNA-binding specificity may be shared by other oncogenic transcription factors.
Our experiments in primary cells also confirm the critical importance of corepressor binding previously shown in the U937-differentiation assay (4) . Paradoxically, in primary cells, a very significant differentiation block remains with the Daxx-tet-RARA*NCoR fusion, whereas immortalization is abolished Fig. 1) . Conversely, in PML͞RARA, SUMO-dependent repression was required for the full differentiation block ex vivo or in vivo, despite the efficient recruitment of SMRT (7) . Finally, massive RARA overexpression induces a major differentiation block, but it does not immortalize primary myeloid progenitor cells in our hands (data not shown). This finding strongly suggests that the molecular determinants of the differentiation block and the immortalization by RARA fusions are not identical.
The experiments reported here demonstrate that enforced RARA homodimerization triggers at least two critical gains of function (enhanced repression and extended target-gene repertoire) that cooperate to yield differentiation arrest and immortalization. That a RARA fusion (Daxx-tet-RARA) devoid of any PML sequence can fully recapitulate PML͞RARA-induced transformation could suggest that the only contribution of PML is to provide the SUMO-dependent repression domain and homodimerization, indicating that disruption of PML nuclear bodies and PML signaling might be dispensable in this ex vivo setting. The complex issue of the minimal requirements for efficient RARA-induced leukemogenesis should now be addressed in vivo.
Materials and Methods
Retroviral Transduction and Cell Analyses. Infection of lineagedepleted bone marrow from 5-fluorouracil-treated C57BL͞6 mice and culture of the transduced progenitors cells with G418 selection in methyl cellulose with stem cell factor, IL-3, IL-6, and granulocyte͞macrophage colony-stimulating factor were performed as described in ref. 18 . After a week, neomycin-selected cells were recovered from methyl cellulose and either analyzed (by FACS, May-Grunwald-Giemsa staining, immunofluorescence, and Western blotting) or replated at a density of 10,000 cells per dish. Cells were serially replated until they stopped growing. Anti-RARA rabbit serum (RP115) was used for immunofluorescence and Western blotting. Daxx-RARA was described in ref. 28 . The tetramerization domain of human p53 (amino acids 324-355) was inserted into a Daxx-RARA construct, yielding Daxx-tet-RARA. The repression domain of mouse SMRT (amino acids 1-1031) was inserted into a Daxx-RARA construct, yielding Daxx-SMRT-RARA. The corepressor-binding sites in RARA (A194T͞H195P) were mutated in the Daxx-tet-RARA construct Daxx-tet-RARA*NCoR, as described in ref. 4 . All of these constructs were cloned in a pMSCV retroviral vector, and the virus was transiently produced by transfection of Plat-E cells (29) . fected with pSG5-RARA mutants were lysed in ice for 30 min in the lysis buffer [50 mM Tris, pH 8.0͞0.6% Igepal CA-630 (Sigma-Aldrich)͞480 mM NaCl͞10% (vol/vol) glycerol͞0.1 mM EDTA͞1 mM DTT͞1.5 mM sodium vanadate͞0.4 mM PMSF͞3 g/ml aprotinin͞1 g/ml pepstatin͞1 g/ml leupeptin]. The centrifugation supernatant was stored at Ϫ80°C. PCRconstructed DNA probes were gel-purified and labeled as described above and mixed with cellular extract in the binding buffer as above with 0.02 g͞l poly(dI-dC) at room temperature. DNA⅐protein complexes and free DNA were separated by electrophoresis on a 3.75% polyacrylamide gel.
Analysis of the
Cell Culture and Transient Transfection. Immortalized MEFs in which the three RARs were excised (20) were retrovirally transduced with the different mutants, grown in DMEM containing 10% FBS, and then treated with 1 M RA (Sigma-Aldrich) overnight. Expressions of RARB, CYP26A1, and transglutaminase type II genes were monitored with the Light Cycler system and genespecific TaqMan probes (Applied Biosystems). The quantification data were analyzed with LightCycler and its software (Roche). ␤ 2 -Microglobulin was used as an internal control.
Reporter plasmids [RARE-3-Tk-Luc and DR5-(or 12)-Tk-Luc (8, 12) ] were transfected into RAR ϩ/ϩ or RAR Ϫ/Ϫ MEFs transduced with the RARA-derived fusions, and luciferase activity was monitored as previously described.
Note. While this manuscript was being reviewed, it was shown that dominant-negative RARA or fusion of histone deacetylase to RARA is unable to initiate APL development in transgenic mice, fully consistent with the data reported here (30) . The AML1-ETO fusion was also shown to undergo multimerization, and multimerization with the expected changes in DNA-binding specificity was shown to be required for transformation (31) .
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